Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
169,9 BRL | +1,88% | +3,77% | -11,73% |
Vakgebied
- verkoop van geneesmiddelen (98,9%): voor de behandeling van HIV (63% van de netto-omzet), COVID-19 (20,4%), hepatitis C-virus (6,6%), hepatitis B-virus (3,6%) en overige (6,4%; voornamelijk cytomegalovirus retinitis, en gevorderd Kaposi sarcoom als gevolg van HIV);
- overige (1,1%): met name royalty's en inkomsten uit onderzoeks- en ontwikkelingsdiensten en uit uitbestede productie van therapeutische producten.
De netto-omzet is als volgt geografisch verdeeld: de Verenigde Staten (69,2%), Europa (16,4%) en overige (14,4%).
Aantal werknemers: 18 000
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Innovative Medicines
100,0
%
| 27 281 | 100,0 % | 27 116 | 100,0 % | -0,60% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
71,7
%
| 18 884 | 69,2 % | 19 438 | 71,7 % | +2,93% |
Europe
15,9
%
| 4 469 | 16,4 % | 4 310 | 15,9 % | -3,56% |
Other International
12,4
%
| 3 928 | 14,4 % | 3 368 | 12,4 % | -14,26% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 59 | 01-03-19 |
Andrew Dickinson
DFI | Director of Finance/CFO | 54 | 01-01-16 |
Flavius Martin
CTO | Chief Tech/Sci/R&D Officer | - | 12-04-21 |
Merdad Parsey
CTO | Chief Tech/Sci/R&D Officer | 61 | 01-11-19 |
Jacquie Ross
IRC | Investor Relations Contact | - | 01-01-21 |
Adam Levy
PRN | Corporate Officer/Principal | - | - |
Stacey Ma
PRN | Corporate Officer/Principal | 54 | 18-07-22 |
Tomas Cihlar
PRN | Corporate Officer/Principal | 57 | - |
Jyoti Mehra
HRO | Human Resources Officer | 48 | 01-11-17 |
Joydeep Ganguly
PRN | Corporate Officer/Principal | - | 01-01-19 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Anthony Welters
BRD | Director/Board Member | 69 | 17-10-20 |
Director/Board Member | 71 | 01-01-18 | |
Ted Love
BRD | Director/Board Member | 65 | 01/02 |
Director/Board Member | 70 | 09-05-18 | |
Javier Rodriguez
BRD | Director/Board Member | 53 | 15-06-20 |
Daniel O'Day
CEO | Chief Executive Officer | 59 | 01-03-19 |
Sandra Horning
BRD | Director/Board Member | 75 | 28-01-20 |
Kelly Kramer
BRD | Director/Board Member | 56 | 19-08-16 |
Director/Board Member | 70 | 07-12-20 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 1 245 853 209 | 1 244 654 868 ( 99,90 %) | 0 | 99,90 % |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
GALAPAGOS NV 25.35% | 16 707 477 | 25.35% | 474 837 523 $ |
ARCUS BIOSCIENCES, INC. 34.67% | 31 532 781 | 34.67% | 464 477 864 $ |
ARCELLX, INC. 12.61% | 6 720 803 | 12.61% | 345 314 858 $ |
4 126 119 | 9.57% | 65 770 337 $ | |
TANGO THERAPEUTICS, INC. 4.55% | 4 854 443 | 4.55% | 35 583 067 $ |
LEAP THERAPEUTICS, INC. 20.78% | 5 319 148 | 20.78% | 16 861 699 $ |
HOOKIPA PHARMA INC. 19.43% | 18 759 465 | 19.43% | 15 120 129 $ |
ASSEMBLY BIOSCIENCES, INC. 19.87% | 1 089 468 | 19.87% | 14 555 292 $ |
ALLOVIR, INC. 14.48% | 16 635 286 | 14.48% | 13 308 229 $ |
XILIO THERAPEUTICS, INC. 19.90% | 7 345 473 | 19.90% | 7 418 928 $ |
Bedrijfsgegevens
Bedrijven van de groep
Naam | Categorie en sector |
---|---|
Gilead Sciences Ireland UC
| |
Gilead Therapeutics A1 Unlimited Co.
Gilead Therapeutics A1 Unlimited Co. Pharmaceuticals: MajorHealth Technology Part of Gilead Sciences, Inc., Gilead Therapeutics A1 Unlimited Co. is an Irish company that develops and manufactures pharmaceutical medicines. The private company is located in Ireland. |
Pharmaceuticals: Major
|
Sector
Verkoop per regio
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+29,36% | 684 mld. | |
+30,21% | 568 mld. | |
-3,96% | 361 mld. | |
+18,39% | 329 mld. | |
+4,52% | 284 mld. | |
+15,96% | 240 mld. | |
+9,50% | 208 mld. | |
-6,75% | 200 mld. | |
+7,80% | 166 mld. |
- Beurs
- Aandelen
- Koers GILD
- Koers GILD34
- Onderneming Gilead Sciences, Inc.